Top ▲

D3 receptor

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 216

Nomenclature: D3 receptor

Family: Dopamine receptors

Contents:

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 400 3q13.31 DRD3 dopamine receptor D3 51
Mouse 7 446 16 28.44 cM Drd3 dopamine receptor D3 43
Rat 7 446 11q21 Drd3 dopamine receptor D3 133
Previous and Unofficial Names Click here for help
D3 receptor | dopamine D3 receptor | dopaminergic receptor D3 | D3R
Database Links Click here for help
Specialist databases
GPCRdb drd3_human (Hs), drd3_mouse (Mm), drd3_rat (Rn)
Other databases
Alphafold P35462 (Hs), P30728 (Mm), P19020 (Rn)
ChEMBL Target CHEMBL234 (Hs), CHEMBL3441 (Mm), CHEMBL3138 (Rn)
DrugBank Target P35462 (Hs)
Ensembl Gene ENSG00000151577 (Hs), ENSMUSG00000022705 (Mm), ENSRNOG00000060806 (Rn)
Entrez Gene 1814 (Hs), 13490 (Mm), 29238 (Rn)
Human Protein Atlas ENSG00000151577 (Hs)
KEGG Gene hsa:1814 (Hs), mmu:13490 (Mm), rno:29238 (Rn)
OMIM 126451 (Hs)
Orphanet ORPHA121179 (Hs)
Pharos P35462 (Hs)
RefSeq Nucleotide NM_000796 (Hs), NM_007877 (Mm), NM_017140 (Rn)
RefSeq Protein NP_000787 (Hs), NP_031903 (Mm), NP_058836 (Rn)
SynPHARM 2633 (in complex with eticlopride)
UniProtKB P35462 (Hs), P30728 (Mm), P19020 (Rn)
Wikipedia DRD3 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Structure of the human dopamine D3 receptor in complex with eticlopride
PDB Id:  3PBL
Ligand:  eticlopride
Resolution:  2.89Å
Species:  Human
References:  26
Natural/Endogenous Ligands Click here for help
dopamine

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]7-OH-DPAT Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Agonist 9.6 pKd 121
⤷ pKd 9.6 (Kd 2.7x10-10 M) [121]
[3H]7-OH-DPAT Small molecule or natural product Ligand is labelled Ligand is radioactive Rn Agonist 9.1 pKd 89
⤷ pKd 9.1 (Kd 7.94x10-10 M) [89]
[3H]PD128907 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Agonist 9.0 pKd 3
⤷ pKd 9.0 (Kd 9.9x10-10 M) [3]
cariprazine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 10.1 pKi 68
⤷ pKi 10.1 (Ki 9x10-11 M) [68]
Description: Binding affinity to human dopamine D3 receptor
lisuride Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 9.6 pKi 103
⤷ pKi 9.6 [103]
cabergoline Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.1 pKi 103
⤷ pKi 9.1 [103]
terguride Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.0 pKi 103
⤷ pKi 9.0 [103]
BP 897 Small molecule or natural product Hs Partial agonist 9.0 pKi 115
⤷ pKi 9.0 (Ki 1x10-9 M) [115]
roxindole Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.9 pKi 103
⤷ pKi 8.9 [103]
pramipexole Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 8.4 – 8.7 pKi 98,124
⤷ pKi 8.4 – 8.7 [98,124]
(-)-N-porphynorapomorphine Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.4 – 8.7 pKi 44,124
⤷ pKi 8.4 – 8.7 [44,124]
rotigotine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.4 pKi 42
⤷ pKi 8.4 (Ki 4x10-9 M) [42]
pergolide Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.3 pKi 103,132
⤷ pKi 8.3 (Ki 5.01x10-9 M) [103,132]
7-OH-DPAT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.1 – 8.4 pKi 18,30,44,90,124
⤷ pKi 7.1 – 8.4 (Ki 7.94x10-8 – 3.98x10-9 M) [18,30,44,90,124]
ropinirole Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 7.7 pKi 57
⤷ pKi 7.7 (Ki 1.9x10-8 M) [57]
apomorphine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Partial agonist 7.7 pKi 133
⤷ pKi 7.7 [133]
7-trans-OH-PIPAT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.7 pKi 30
⤷ pKi 7.7 [30]
bromocriptine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 7.1 – 8.2 pKi 44,103,124
⤷ pKi 7.1 – 8.2 [44,103,124]
PD 128907 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.6 – 7.7 pKi 118,124
⤷ pKi 7.6 – 7.7 (Ki 2.51x10-8 – 1.99x10-8 M) [118,124]
quinpirole Small molecule or natural product Click here for species-specific activity table Rn Full agonist 7.3 – 7.8 pKi 18,133
⤷ pKi 7.3 – 7.8 [18,133]
quinelorane Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.2 – 7.4 pKi 104,132
⤷ pKi 7.2 – 7.4 [104,132]
quinpirole Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.4 – 8.0 pKi 18,98,104,112,124,132-133,144
⤷ pKi 6.4 – 8.0 (Ki 3.98x10-7 – 1x10-8 M) [18,98,104,112,124,132-133,144]
bromocriptine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Full agonist 7.1 pKi 133
⤷ pKi 7.1 [133]
dopamine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 6.4 – 7.3 pKi 18,44,124,133
⤷ pKi 6.4 – 7.3 [18,44,124,133]
apomorphine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 6.1 – 7.6 pKi 18,44,103,124,132
⤷ pKi 6.1 – 7.6 [18,44,103,124,132]
compound 3 [PMID: 23134120] Small molecule or natural product Click here for species-specific activity table Hs Agonist 6.8 pKi 136
⤷ pKi 6.8 (Ki 1.68x10-7 M) [136]
piribedil Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.6 pKi 103
⤷ pKi 6.6 [103]
HS665 Small molecule or natural product Click here for species-specific activity table Hs Agonist 6.6 pKi 136
⤷ pKi 6.6 (Ki 2.82x10-7 M) [136]
vilazodone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.2 pIC50 58
⤷ pIC50 7.2 (IC50 7.1x10-8 M) [58]
PF-592379 Small molecule or natural product Click here for species-specific activity table Hs Agonist 6.7 pIC50 32
⤷ pIC50 6.7 (IC50 2.15x10-7 M) [32]
View species-specific agonist tables
Agonist Comments
PF-592379 has no measurable binding to D1, D2 or D5 receptors [32].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]nemonapride Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Antagonist 10.3 pKd 91
⤷ pKd 10.3 [91]
[3H]spiperone Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Ligand has a PDB structure Rn Antagonist 9.9 pKd 60,157
⤷ pKd 9.9 (Kd 1.25x10-10 M) [60,157]
S33084 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.6 pKi 102
⤷ pKi 9.6 (Ki 2.5x10-10 M) [102]
perospirone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 9.6 pKi 132
⤷ pKi 9.6 (Ki 2.8x10-10 M) [132]
R-VK4-40 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.5 pKi 63
⤷ pKi 9.5 (Ki 2.9x10-10 M) [63]
nafadotride Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.5 pKi 125
⤷ pKi 9.5 (Ki 3x10-10 M) [125]
nemonapride Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.2 – 9.3 pKi 90,141
⤷ pKi 9.2 – 9.3 [90,141]
spiperone Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.2 pKi 133
⤷ pKi 9.2 [133]
PG01037 Small molecule or natural product Hs Antagonist 9.2 pKi 55
⤷ pKi 9.2 [55]
flupentixol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 9.0 pKi 44
⤷ pKi 9.0 (Ki 1.1x10-9 M) [44]
eticlopride Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.8 pKi 90,141
⤷ pKi 8.8 [90,141]
NGB 2904 Small molecule or natural product Hs Antagonist 8.8 pKi 149
⤷ pKi 8.8 [149]
sertindole Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 8.0 – 8.8 pKi 6,127,129
⤷ pKi 8.0 – 8.8 (Ki 1x10-8 – 1.6x10-9 M) [6,127,129]
prochlorperazine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.4 pKi 9
⤷ pKi 8.4 (Ki 4.45x10-9 M) [9]
chlorprothixene Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.3 pKi 145
⤷ pKi 8.3 (Ki 4.56x10-9 M) [145]
zotepine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.2 pKi 127
⤷ pKi 8.2 (Ki 6.4x10-9 M) [127]
(+)-sulpiride Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.1 pKi 92
⤷ pKi 8.1 (Ki 7.99x10-9 M) [92]
haloperidol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.5 – 8.6 pKi 44,130,132,143
⤷ pKi 7.5 – 8.6 [44,130,132,143]
SB 277011-A Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.0 pKi 119
⤷ pKi 8.0 (Ki 1x10-8 M) [119]
raclopride Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.9 pKi 104
⤷ pKi 7.9 [104]
pimozide Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.0 – 8.6 pKi 44,132
⤷ pKi 7.0 – 8.6 [44,132]
loxapine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 7.7 pKi 129
⤷ pKi 7.7 (Ki 2.1x10-8 M) [129]
mesoridazine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.6 pKi 29
⤷ pKi 7.6 (Ki 2.3x10-8 M) [29]
raclopride Small molecule or natural product Click here for species-specific activity table Rn Antagonist 7.5 pKi 133
⤷ pKi 7.5 [133]
(+)-butaclamol Small molecule or natural product Click here for species-specific activity table Rn Antagonist 7.3 – 7.5 pKi 18
⤷ pKi 7.3 – 7.5 [18]
pimozide Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Antagonist 7.4 pKi 133
⤷ pKi 7.4 [133]
amisulpride Small molecule or natural product Approved drug Rn Antagonist 7.4 pKi 133
⤷ pKi 7.4 [133]
(+)-S-14297 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.9 – 7.9 pKi 100,104
⤷ pKi 6.9 – 7.9 (Ki 1.26x10-7 – 1.3x10-8 M) [100,104]
(+)-butaclamol Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.7 – 8.0 pKi 44,118,141
⤷ pKi 6.7 – 8.0 [44,118,141]
chlorpromazine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.2 – 7.5 pKi 44,132
⤷ pKi 7.2 – 7.5 [44,132]
domperidone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 7.1 – 7.6 pKi 44,132
⤷ pKi 7.1 – 7.6 [44,132]
sulpiride Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.8 – 7.8 pKi 18
⤷ pKi 6.8 – 7.8 (Ki 1.42x10-7 – 1.4x10-8 M) [18]
chlorpromazine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Antagonist 7.2 pKi 133
⤷ pKi 7.2 [133]
(+)-UH232 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.0 – 7.4 pKi 44,133
⤷ pKi 7.0 – 7.4 [44,133]
(-)-sulpiride Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 6.7 – 7.7 pKi 44,132,141
⤷ pKi 6.7 – 7.7 (Ki 2.07x10-7 – 2x10-8 M) [44,132,141]
haloperidol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Antagonist 7.0 pKi 133
⤷ pKi 7.0 [133]
risperidone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.0 pKi 104
⤷ pKi 7.0 [104]
(+)-UH232 Small molecule or natural product Click here for species-specific activity table Rn Antagonist 7.0 pKi 133
⤷ pKi 7.0 [133]
domperidone Small molecule or natural product Approved drug Click here for species-specific activity table Rn Antagonist 7.0 pKi 133
⤷ pKi 7.0 [133]
promazine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.8 pKi 19
⤷ pKi 6.8 (Ki 1.59x10-7 M) [19]
trans-flupenthixol Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.5 pKi 44
⤷ pKi 6.5 (Ki 3x10-7 M) [44]
(+)-sulpiride Small molecule or natural product Click here for species-specific activity table Rn Antagonist 6.4 pKi 133
⤷ pKi 6.4 [133]
(+)-AJ76 Small molecule or natural product Hs Antagonist 5.9 – 6.2 pKi 104,132
⤷ pKi 5.9 – 6.2 [104,132]
(+)-AJ76 Small molecule or natural product Rn Antagonist 6.0 pKi 133
⤷ pKi 6.0 [133]
clozapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.2 – 6.3 pKi 44,132
⤷ pKi 5.2 – 6.3 [44,132]
clozapine Small molecule or natural product Approved drug Click here for species-specific activity table Rn Antagonist 5.7 pKi 133
⤷ pKi 5.7 [133]
View species-specific antagonist tables
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
SB269652 Small molecule or natural product Click here for species-specific activity table Hs Negative ~9.0 pKi 45
⤷ pKi ~9.0 (Ki ~1x10-9 M) [45]
Immuno Process Associations
Immuno Process:  Antigen presentation
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Adenylyl cyclase inhibition
Potassium channel
References:  27,86,116-117,128
Tissue Distribution Click here for help
Ventral striatum/nucleus accumbens > neostriatum, cerebral cortex, cerebellar cortex.
Species:  Human
Technique:  Autoradiography.
References:  59,76
Brain: nucleus accumbens and islands of Calleja.
Species:  Human
Technique:  in situ hybridization.
References:  78
Brain: mesencephalic dopamine neurons in substantia nigra and ventral tegmental area.
Species:  Rat
Technique:  In situ hybridization.
References:  41
Kidney: proximal tubules
Species:  Rat
Technique:  Immunohistochemistry
References:  108
Brain: Post-synaptic elements of asymmetric synapses of the nucleus accumbens
Species:  Rat
Technique:  Immuno-electron microscopy
References:  87,134
Brain: islands of Cajella, olafactory bulb, pituitary intermediate lobe > nucleus accumbens, molecular layer of the vestibulocerebellum, substantia nigra pars compacta.
Species:  Rat
Technique:  Autoradiography and in situ hybridization.
References:  12,40,48,77,83,89,111,120
Accumbens nucleus, islands of Calleja, bed nucleus of the stria terminalis, hippocampus, mammillary nuclei, substantia nigra.
Species:  Rat
Technique:  in situ hybridization.
References:  14
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of extracellular acidification in CHO cells transfected with the human D3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification.
References:  17
Measurement of adenylyl cyclase activity in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Inhibition of adenylyl cyclase.
References:  27
Measurement of extracellular acidification rates in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification rates.
References:  27
Measurement of extracellular acidification and D3 receptor membrane density in C6 glioma cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  C6 glioma cells.
Response measured:  Increase in extracellular acidification rate and receptor density.
References:  34
Measurement of c-fos activation and increased mitogenesis in neuroblastoma-glioma hybrid cells (NG108-15) transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in c-fos activation and mitogenesis.
References:  116
Measurement of cAMP accumulation in cultured Xenopus laevis melanophores transfected with the human D3 receptor.
Species:  Human
Tissue:  Cultured Xenopus laevis melanophores.
Response measured:  Inhibition of cAMP accumulation.
References:  117
Measurement of whole-cell potassium current in NG108-15 cells tranfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Reduction of peak whole-cell potassium current.
References:  86
Measurement of activation of GIRK1 in Xenopus oocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1.
References:  148
Measurement of mitogenesis in NG108-15 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in mitogenesis.
References:  124
Measurement of melanocyte aggregation in Xenopus melanocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus melanocytes.
Response measured:  Stimulation of melanocyte aggregation.
References:  17,118
Measurement of activation of an 85 pS K+ channel known to be activated by dopamine and the "D2-like" agonist quinpirole.
Species:  Human
Tissue:  Freshly dissociated rat caudate-putamen neurons.
Response measured:  Activation of K+ channel.
References:  85
Measurement of dopamine release from a mesencephalic clonal cell line transfected with the D3 receptor.
Species:  Human
Tissue:  Neuronal mesencephalic MN9D cells.
Response measured:  Inhibition of dopamine release.
References:  142
Measurement of K+-stimulated tyrosine hydroxylase activity in D3 receptor-expressing MN9D cells.
Species:  Human
Tissue:  MN9D cells
Response measured:  Decrease in K+-stimulated tyrosine hydroxylase activity.
References:  109
Measurement of cAMP levels in HEK 293 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  94
Measurement of Cl- currents in Xenopus oocytes transfected with murine D3L and D3S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  131
Measurement of β-arrestin translocation in CHO cells with the human D3 receptor.
Species:  Human
Tissue:  CHO cells
Response measured:  β-arrestin translocation
References:  11,97,151
Physiological Functions Click here for help
Inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  37,118
Activation increases cell division.
Species:  Rat
Tissue:  CHO cells.
References:  27
Stimulation of the D3 receptor decreases the rate of food-reinforced responding in a fixed-ratio operant paradigm.
Species:  Rat
Tissue:  In vivo.
References:  123
Inhibition of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  2,36,38,49,65,67,70,84,95,118,125,139-140,146-147
Modulation of motor activity.
Species:  Mouse
Tissue:  In vivo.
References:  137
Stimulation of yawning and hypothermia.
Species:  Rat
Tissue:  In vivo.
References:  2,37,67,73,99-100,104
Modulation of sniffing behaviour.
Species:  Rat
Tissue:  In vivo.
References:  36
Modulation of penile erection and ejaculatory behaviour.
Species:  Rat
Tissue:  In vivo.
References:  21,73
Modulation of self-administration of cocaine.
Species:  Rat
Tissue:  In vivo.
References:  20
Modulation of self-stimulation of the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  38
Modulation of reinforcing effects of cocaine and d-amphetamine.
Species:  Rat
Tissue:  In vivo.
References:  69
Stimulation of the D3 receptor produces an aversive effect in a conditioned place-preference paradigm.
Species:  Rat
Tissue:  In vivo.
References:  25
Hyperpolarization of neurons and inhibition of cell firing.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area of rat brain slices.
References:  15
A D3 agonist with relative selectivity for the dopamine D3 receptor, inhibits the firing of both A9 and A10 dopamine neurons and causes current-dependent inhibitions of spontaneously active or glutamate-driven caudate-putamen and nucleus accumbens neurons.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area dopamine neurons, and caudate-putamen and nucleus accumbens neurons in vivo.
References:  85
Systemic administration of a D3 receptor agonist decreases extracellular dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the nucleus accumbens and dopaminergic neuronal activity in the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  39
A D3 agonist inhibits substantia nigra pars compacta dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  72
A D3 agonist inhibits ventral tagmental area dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  81
Administration of a D3 agonist to freely moving rats decreases dialysate levels of dopamine in the nucleus accumbens.
Species:  Rat
Tissue:  In vivo.
References:  122
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  154
Modulation of dopamine synthesis.
Species:  Rat
Tissue:  In vivo.
References:  5,46,53,118
Blockade of the D3 receptor inhibits dizocilpine (MK-801)-induced hyperactivity.
Species:  Mouse
Tissue:  In vivo.
References:  82
Blockade of the D3 receptor disrupts drug-associated cue-induced craving and stress-induced craving.
Species:  Rat
Tissue:  In vivo.
References:  4,24,47,50,113,115,150
Blockade of the D3 receptor enhances monoaminergic and cholinergic neurotransmission.
Species:  Rat
Tissue:  In vivo.
References:  74-75,101-102
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  154
Modulation by the D3 receptor of drug-induced place preference.
Species:  Rat
Tissue:  In vivo.
References:  7,10,23,56,61
Reciprocal regulation of D3 receptor and NMDA receptor through Ca2+/calmodulin-dependent protein kinase II
Species:  Rat
Tissue:  GST-constructs and nucleus accumbens extracts.
References:  87
Selective D3 antagonists induced positive cerebral blood volume (CBV) changes whereas D3 agonism using 7-OH-DPAT induced negative CBV changes.
Species:  Rat
Tissue:  Nucleus accumbens, antero-medial striatum, cingulate cortex, thalamus, interpeduncular region and hypothalamus.
References:  28
Regulation of renal function and blood pressure by D3 receptors.
Species:  Rat
Tissue:  In vivo.
References:  88,155-156
Physiological Consequences of Altering Gene Expression Click here for help
D3 receptor knockout mice exhibit altered circadian pattern in spinal dopamine synthesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
D3 receptor knockout mice exhibit higher basal levels of extracellular dopamine compared to the wild-type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  33,64
D3 receptor knockout mice display enhanced hyperactivity when compared to the wild-type, although these effects may be limited.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1,13,153
D3 receptor knockout mice display a transient increase in activity in a novel environment compared with wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  71,152
D3 receptor knockout mice exhibit increased behavioural sensitivity to combined injections of D1 and D2 class receptor agonists, cocaine and amphetamine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  153
D3 receptor knockout mice exhibit reduced anxiety.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  138
D3 receptor knockout mice exhibit renin-dependent hypertension.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  8
D3 receptor knockout mice exhibit increased gene expression in striatal neurons following acute administration of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22
D3 receptor knockout mice exhibit aggravation of the development of physical dependence on ethanol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  107
D3 receptor knockout mice exhibit increased morphine-induced rewarding effects and potentiation of morphine-induced hyperlocomotion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  106
D3 receptor knockout mice display similar effects (reward/intake) of ethanol as wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16
D3 receptor knockout mice exhibit increased D1/D2 receptor-mediated intracellular signalling.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  105
D3 receptor knockout mice exhibit increased adiposity induced by a high-fat diet.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  96
D3 receptor knockout mice exhibit neuroadaptive changes which support the role of D3 receptors as autoreceptors.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  80
D3 receptor knockout mice display increased susceptibility to cocaine addition
Species:  Mouse
Tissue: 
Technique:  Gene knockout
References:  135
Dopamine is more efficacious at the D3 receptor Gly9 compared to Ser9 variant.
Species:  Human
Tissue:  HEK293 cells
Technique:  Binding, adenylate cyclase inhibition, MAPK phosphorylation
References:  62
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
+|Cm|Drd3tm1Stl Cm/+,Drd3tm1Stl/Drd3tm1Stl
involves: 101/H * 129S2/SvPas * C3H/HeH * C3H/HeSn * C57BL/6J		 MGI:88424  MGI:94925  MP:0009748 abnormal behavioral response to addictive substance PMID: 19840852 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001454 abnormal cued conditioning behavior PMID: 9354330 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005449 abnormal food intake PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0000676 abnormal water content PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 16525059 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd		 MGI:94925  MP:0005643 decreased dopamine level PMID: 12044470 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001505 hunched posture PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005669 increased circulating leptin level PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003867 increased defecation PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003911 increased drinking behavior PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003909 increased eating behavior PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005458 increased percent body fat PMID: 15084447 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd		 MGI:94925  MP:0001409 increased stereotypic behavior PMID: 12044470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005455 increased susceptibility to weight gain PMID: 15084447 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0010024 increased total body fat amount PMID: 15084447 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0002082 postnatal lethality PMID: 10391470 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Major affective disorder 1; MAFD1
Synonyms: Bipolar affective disorder
Manic depressive-psychosis
OMIM: 125480
Role:  The Ba1I polymorphism has been associated with bipolar disorder
References:  110
Disease:  Schizophrenia
Disease Ontology: DOID:5419
OMIM: 181500
Orphanet: ORPHA3140
Role:  The Ba1I restriction fragment length polymorphism (corresponding to a point mutation in the 1st exon and resulting in a serine-to-glycine substitution in the N-terminal extracellular domain of the receptor) has been associated with schizophrenia.
References:  35,66,93
Disease:  Tremor, hereditary essential, 1; ETM1
Synonyms: Essential tremor [Disease Ontology: DOID:4990]
Hereditary essential tremor [Orphanet: ORPHA862]
Disease Ontology: DOID:4990
OMIM: 190300
Orphanet: ORPHA862
Comments:  Gly9 variant confers disease risk
References:  62
Click column headers to sort
Type Species Amino acid change Nucleotide change Description Reference
Missense Human S9G Gain of function mutation. Functional variant of the dopamine D3 receptor which is associated with risk and age-at-onset of essential tremor 62
General Comments
Alternative splicing leads to a 425aa isoform in mouse [43] and several shorter presumably inactive isoforms in rat [52] and human [126]. Two polymorphic variants [Ser9] and [Gly9] in human [79]. The organization of the coding sequence of the human gene has been established [54]. Anti-psychotic drugs display closely similar or slightly lower antagonist affinity at D3 compared to D2 receptors. S(+)14297, initially reported as a D3 receptor antagonist [104] displays full agonist activity in two functional assays [114].

References

Show »

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR et al.. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA, 93 (5): 1945-9. [PMID:8700864]

2. Ahlenius S, Salmi P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol, 260 (2-3): 177-81. [PMID:7988642]

3. Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD, Pugsley TA. (1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci, 57 (15): 1401-10. [PMID:7674830]

4. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. (2003) Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology, 28 (7): 1272-80. [PMID:12700694]

5. Aretha CW, Sinha A, Galloway MP. (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther, 274 (2): 609-13. [PMID:7636720]

6. Arnt J, Skarsfeldt T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 18 (2): 63-101. [PMID:9430133]

7. Ashby Jr CR, Paul M, Gardner EL, Heidbreder CA, Hagan JJ. (2003) Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse, 48 (3): 154-6. [PMID:12645041]

8. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, Jose PA. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest, 102 (3): 493-8. [PMID:9691085]

9. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

10. Aujla H, Beninger RJ. (2005) The dopamine D(3) receptor-preferring partial agonist BP 897 dose-dependently attenuates the expression of amphetamine-conditioned place preference in rats. Behav Pharmacol, 16 (3): 181-6. [PMID:15864073]

11. Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH. (2011) N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem, 54 (10): 3581-94. [PMID:21495689]

12. Booze RM, Wallace DR. (1995) Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse, 19 (1): 1-13. [PMID:7709338]

13. Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ. (1999) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology, 38 (4): 555-65. [PMID:10221759]

14. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res, 564 (2): 203-19. [PMID:1839781]

15. Bowery B, Rothwell LA, Seabrook GR. (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol, 112 (3): 873-80. [PMID:7921615]

16. Boyce-Rustay JM, Risinger FO. (2003) Dopamine D3 receptor knockout mice and the motivational effects of ethanol. Pharmacol Biochem Behav, 75 (2): 373-9. [PMID:12873629]

17. Boyfield I, Winn F, Coldwell M. (1996) Comparison of agonist potencies at human dopamine D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem Soc Trans, 24: 57S-57S. [PMID:8674731]

18. Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF, Molinoff PB. (1995) Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology, 12 (4): 335-45. [PMID:7576010]

19. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U et al.. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther, 315 (3): 1278-87. [PMID:16135699]

20. Caine SB, Koob GF. (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science, 260 (5115): 1814-6. [PMID:8099761]

21. CARLSSON A, LINDQVIST M, MAGNUSSON T. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180 (4596): 1200. [PMID:13483658]

22. Carta AR, Gerfen CR, Steiner H. (2000) Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport, 11 (11): 2395-9. [PMID:10943692]

23. Cervo L, Burbassi S, Colovic M, Caccia S. (2005) Selective antagonist at D3 receptors, but not non-selective partial agonists, influences the expression of cocaine-induced conditioned place preference in free-feeding rats. Pharmacol Biochem Behav, 82 (4): 727-34. [PMID:16405981]

24. Cervo L, Cocco A, Petrella C, Heidbreder CA. (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol, 10 (2): 167-81. [PMID:16426478]

25. Chaperon F, Thiébot MH. (1996) Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol, 7 (1): 105-109. [PMID:11224401]

26. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V et al.. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 330 (6007): 1091-5. [PMID:21097933]

27. Chio CL, Lajiness ME, Huff RM. (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol, 45 (1): 51-60. [PMID:8302280]

28. Choi JK, Mandeville JB, Chen YI, Grundt P, Sarkar SK, Newman AH, Jenkins BG. (2010) Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology (Berl.), 212 (1): 59-72. [PMID:20628733]

29. Choi S, Haggart D, Toll L, Cuny GD. (2004) Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett, 14 (17): 4379-82. [PMID:15357957]

30. Chumpradit S, Kung MP, Vessotskie J, Foulon C, Mu M, Kung HF. (1994) Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem, 37 (24): 4245-50. [PMID:7990123]

31. Clemens S, Sawchuk MA, Hochman S. (2005) Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D3 receptor knockout mice. Neuroscience, 133 (2): 353-7. [PMID:15878801]

32. Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB. (2012) Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol, 23 (3): 280-91. [PMID:22470105]

33. Cooper DC, Loeltzow TE, Xu M, Tonegawa S, White FJ, Wolf ME. (1996) Regulations of dopamine release and synthesis in dopamine D3R receptor knockout mice. (Abstract) Soc Neurosci Abst, 22: 1319-.

34. Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, Neve KA. (1995) Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse, 21 (1): 1-9. [PMID:8525456]

35. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC et al.. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet, 29 (12): 858-60. [PMID:1362221]

36. Daly SA, Waddington JL. (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology, 32 (5): 509-10. [PMID:8321432]

37. Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikström H. (1993) Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol, 249 (3): R9-10. [PMID:8287911]

38. Depoortere R, Perrault G, Sanger DJ. (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl.), 124 (3): 231-40. [PMID:8740044]

39. Devoto P, Collu M, Muntoni AL, Pistis M, Serra G, Gessa GL, Diana M. (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse, 20 (2): 153-5. [PMID:7570345]

40. Diaz J, Lévesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC, Sokoloff P. (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience, 65 (3): 731-45. [PMID:7609872]

41. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P. (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci, 20 (23): 8677-84. [PMID:11102473]

42. Dijkstra D, Rodenhuis N, Vermeulen ES, Pugsley TA, Wise LD, Wikström HV. (2002) Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. J Med Chem, 45 (14): 3022-31. [PMID:12086487]

43. Fishburn CS, Belleli D, David C, Carmon S, Fuchs S. (1993) A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J Biol Chem, 268 (8): 5872-8. [PMID:8449953]

44. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther, 268 (1): 417-26. [PMID:8301582]

45. Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD et al.. (2015) Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol, 25 (9): 1448-61. [PMID:25583363]

46. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol, 308 (3): 261-9. [PMID:8858296]

47. Galaj E, Ananthan S, Saliba M, Ranaldi R. (2014) The effects of the novel DA D3 receptor antagonist SR 21502 on cocaine reward, cocaine seeking and cocaine-induced locomotor activity in rats. Psychopharmacology (Berl.), 231 (3): 501-10. [PMID:24037509]

48. Gehlert DR, Gackenheimer SL, Seeman P, Schaus J. (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol, 211 (2): 189-94. [PMID:1351846]

49. Gilbert DB, Cooper SJ. (1995) 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?. Pharmacol Biochem Behav, 52 (2): 275-80. [PMID:8577791]

50. Gilbert JG, Newman AH, Gardner EL, Ashby Jr CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX. (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse, 57 (1): 17-28. [PMID:15858839]

51. Giros B, Martres M-P, Sokoloff P, Schwartz J-C. (1990) cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C R Acad Sci III, 311: 501-508. [PMID:2129115]

52. Giros B, Martres MP, Pilon C, Sokoloff P, Schwartz JC. (1991) Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem Biophys Res Commun, 176: 1584-1592. [PMID:2039532]

53. Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther, 275 (2): 899-913. [PMID:7473181]

54. Griffon N, Crocq MA, Pilon C, Martres MP, Mayerova A, Uyanik G, Burgert E, Duval F, Macher JP, Javoy-Agid F et al.. (1996) Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet, 67 (1): 63-70. [PMID:8678117]

55. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem, 50 (17): 4135-46. [PMID:17672446]

56. Hachimine P, Seepersad N, Ananthan S, Ranaldi R. (2014) The novel dopamine D3 receptor antagonist, SR 21502, reduces cocaine conditioned place preference in rats. Neurosci Lett, 569: 137-41. [PMID:24704326]

57. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ et al.. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J Med Chem, 40 (5): 639-46. [PMID:9057850]

58. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem, 47 (19): 4684-92. [PMID:15341484]

59. Herroelen L, De Backer JP, Wilczak N, Flamez A, Vauquelin G, De Keyser J. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res, 648 (2): 222-8. [PMID:7922537]

60. Hoare SR, Coldwell MC, Armstrong D, Strange PG. (2000) Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol, 130 (5): 1045-59. [PMID:10882389]

61. Hu R, Song R, Yang R, Su R, Li J. (2013) The dopamine D3 receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats. Eur J Pharmacol, (1-3). [PMID:24513519]

62. Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, Sokoloff P. (2006) A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci USA, 103 (28): 10753-8. [PMID:16809426]

63. Jordan CJ, Humburg B, Rice M, Bi GH, You ZB, Shaik AB, Cao J, Bonifazi A, Gadiano A, Rais R et al.. (2019) The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology, 158: 107597. [PMID:30974107]

64. Joseph JD, Wang YM, Miles PR, Budygin EA, Picetti R, Gainetdinov RR, Caron MG, Wightman RM. (2002) Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience, 112 (1): 39-49. [PMID:12044470]

65. Kagaya T, Yonaga M, Furuya Y, Hashimoto T, Kuroki J, Nishizawa Y. (1996) Dopamine D3 agonists disrupt social behavior in rats. Brain Res, 721 (1-2): 229-32. [PMID:8793104]

66. Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, Lieberman J, Buchanan JA. (1995) Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet, 60 (6): 558-62. [PMID:8825896]

67. Khroyan TV, Baker DA, Neisewander JL. (1995) Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl.), 122 (4): 351-7. [PMID:8657832]

68. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I et al.. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther, 333 (1): 328-40. [PMID:20093397]

69. Kling-Petersen T, Ljung E, Svensson K. (1994) The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav, 49 (2): 345-51. [PMID:7824548]

70. Kling-Petersen T, Ljung E, Svensson K. (1995) Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect, 102 (3): 209-20. [PMID:8788069]

71. Koeltzow T, Cooper DC, Hu X-T, Xu M, Tonegawa S, White FJ. (1995) In vivo effects of dopaminergic ligands on dopamine D3 receptor deficient mice. (Abstract) Soc Neurosci Abst, 21: 364-.

72. Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol, 277: 209-214. [PMID:7493610]

73. Kurashima M, Yamada K, Nagashima M, Shirakawa K, Furukawa T. (1995) Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav, 52 (3): 503-8. [PMID:8545466]

74. Lacroix LP, Ceolin L, Zocchi A, Varnier G, Garzotti M, Curcuruto O, Heidbreder CA. (2006) Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods, 157 (1): 25-31. [PMID:16697046]

75. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA. (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology, 28 (5): 839-49. [PMID:12637956]

76. Lahti RA, Roberts RC, Tamminga CA. (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport, 6 (18): 2505-12. [PMID:8741751]

77. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci, 5 (2): 145-53. [PMID:8261096]

78. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res, 18 (1-2): 187-92. [PMID:8097550]

79. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz JC. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet, 2: 249-256.

80. Le Foll B, Diaz J, Sokoloff P. (2005) Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci, 76: 1281-1296. [PMID:15642598]

81. Lejeune F, Millan MJ. (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol, 275 (3): R7-9. [PMID:7768288]

82. Leriche L, Schwartz JC, Sokoloff P. (2003) The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology, 45 (2): 174-81. [PMID:12842123]

83. Levant B, Grigoriadis DE, DeSouza EB. (1992) Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther, 262 (3): 929-35. [PMID:1356154]

84. Levant B, Vansell NR. (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology, 17 (2): 67-71. [PMID:9252981]

85. Liu JC, Cox RF, Greif GJ, Freedman JE, Waszczak BL. (1994) The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol, 264: 269-278. [PMID:7698165]

86. Liu LX, Monsma Jr FJ, Sibley DR, Chiodo LA. (1996) D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse, 24 (2): 156-64. [PMID:8890457]

87. Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, Zhou HF, Xu M, Wang JQ. (2009) Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron, 61 (3): 425-38. [PMID:19217379]

88. Luippold G, Beilharz M, Wehrmann M, Unger L, Gross G, Mühlbauer B. (2005) Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol, 371 (5): 420-7. [PMID:15887004]

89. Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA, 89 (17): 8155-9. [PMID:1518841]

90. MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL. (1994) Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol, 266 (1): 79-85. [PMID:7907989]

91. Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU. (2003) Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem, 87 (3): 631-41. [PMID:14535946]

92. Malmberg A, Jackson DM, Eriksson A, Mohell N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol, 43 (5): 749-54. [PMID:8099194]

93. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ. (1994) Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet, 54 (1): 21-6. [PMID:7909989]

94. McAllister G, Knowles MR, Ward-Booth SM, Sinclair HA, Patel S, Marwood R, Emms F, Patel S, Smith A, Seabrook GR et al.. (1995) Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells. J Recept Signal Transduct Res, 15 (1-4): 267-81. [PMID:8903944]

95. McElroy J, Zeller KL, Amy KA, Ward KA, Cawley JF, Mazzola AL, Keim W, Rohrbach K. (1993) In vivo agonist properties of 7-hydroxy-N,N-Di-N-propyl-2-aminotetralin, a dopamine D3-selective receptor ligand. Drug Development Research, 30: 257-259.

96. McQuade JA, Benoit SC, Xu M, Woods SC, Seeley RJ. (2004) High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res, 151 (1-2): 313-9. [PMID:15084447]

97. Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (2015) (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology (Berl.), 232 (5): 917-30. [PMID:25231919]

98. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol, 290 (1): 29-36. [PMID:7664822]

99. Millan MJ, Audinot V, Melon C, Newman-Tancredi A. (1995) Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol, 280 (2): 225-9. [PMID:7589191]

100. Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL. (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol, 260 (2-3): R3-5. [PMID:7988633]

101. Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A. (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem, 100 (4): 1047-61. [PMID:17266737]

102. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 293 (3): 1048-62. [PMID:10869410]

103. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303 (2): 791-804. [PMID:12388666]

104. Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther, 275: 885-898. [PMID:7473180]

105. Mizuo K, Narita M, Miyatake M, Suzuki T. (2004) Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor. Neurosci Lett, 358 (1): 13-6. [PMID:15016423]

106. Narita M, Mizuo K, Mizoguchi H, Sakata M, Narita M, Tseng LF, Suzuki T. (2003) Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J Neurosci, 23 (3): 1006-12. [PMID:12574430]

107. Narita M, Soma M, Tamaki H, Narita M, Suzuki T. (2002) Intensification of the development of ethanol dependence in mice lacking dopamine D(3) receptor. Neurosci Lett, 324 (2): 129-32. [PMID:11988344]

108. Nürnberger A, Räbiger M, Mack A, Diaz J, Sokoloff P, Mühlbauer B, Luippold G. (2004) Subapical localization of the dopamine D3 receptor in proximal tubules of the rat kidney. J Histochem Cytochem, 52 (12): 1647-55. [PMID:15557219]

109. O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD. (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther, 277 (1): 186-92. [PMID:8613917]

110. Parsian A, Chakraverty S, Todd RD. (1995) Possible association between the dopamine D3 receptor gene and bipolar affective disorder. Am J Med Genet, 60 (3): 234-7. [PMID:7573178]

111. Parsons B, Stanley M, Javitch J. (1993) Differential visualization of dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol, 234 (2-3): 269-72. [PMID:8097723]

112. Patel S, Patel S, Marwood R, Emms F, Marston D, Leeson PD, Curtis NR, Kulagowski JJ, Freedman SB. (1996) Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol, 50 (6): 1658-64. [PMID:8967990]

113. Peng XQ, Ashby Jr CR, Spiller K, Li X, Li J, Thomasson N, Millan MJ, Mocaër E, Muńoz C, Gardner EL et al.. (2009) The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology, 56 (4): 752-60. [PMID:19136017]

114. Perachon S, Betancur C, Pilon C, Rostène W, Schwartz JC, Sokoloff P. (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport, 11 (1): 221-5. [PMID:10683862]

115. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature, 400 (6742): 371-5. [PMID:10432116]

116. Pilon C, Lévesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC, Sokoloff P. (1994) Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol, 268 (2): 129-39. [PMID:7957635]

117. Potenza MN, Graminski GF, Schmauss C, Lerner MR. (1994) Functional expression and characterization of human D2 and D3 dopamine receptors. J Neurosci, 14 (3 Pt 2): 1463-76. [PMID:7907363]

118. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW et al.. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther, 275 (3): 1355-66. [PMID:8531103]

119. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC et al.. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther, 294 (3): 1154-65. [PMID:10945872]

120. Ricci A, Vega JA, Mammola CL, Amenta F. (1995) Localisation of dopamine D3 receptor in the rat cerebellar cortex: a light microscope autoradiographic study. Neurosci Lett, 190 (3): 163-6. [PMID:7637884]

121. Ricci A, Veglio F, Amenta F. (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J Neuroimmunol, 58 (2): 139-44. [PMID:7759603]

122. Rivet JM, Audinot V, Gobert A, Peglion JL, Millan MJ. (1994) Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol, 265 (3): 175-7. [PMID:7875234]

123. Sanger DJ, Depoortere R, Perrault G. (1996) Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol, 7 (5): 477-482. [PMID:11224444]

124. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, Sokoloff P. (1995) A functional test identifies dopamine agonists selective for D3versus D2receptors. Neuroreport, 6: 329-332. [PMID:7756621]

125. Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A et al.. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther, 275 (3): 1239-46. [PMID:8531087]

126. Schmauss C, Haroutunian V, Davis KL, Davidson M. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA, 90 (19): 8942-6. [PMID:8415635]

127. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.), 124 (1-2): 57-73. [PMID:8935801]

128. Seabrook GR, Patel S, Marwood R, Emms F, Knowles MR, Freedman SB, McAllister G. (1992) Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett, 312 (2-3): 123-6. [PMID:1330688]

129. Seeman P. (2001) Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research, 1 (1-2): 53-60. DOI: 10.1016/S1566-2772(00)00007-4

130. Shahid M, Walker GB, Zorn SH, Wong EH. (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (Oxford), 23 (1): 65-73. [PMID:18308814]

131. Skaaning Jensen B, Levavi-Sivan B, Fishburn CS, Fuchs S. (1997) Functional expression of the murine D2, D3, and D4 dopamine receptors in Xenopus laevis oocytes. FEBS Lett, 420: 191-195. [PMID:9459308]

132. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres MP, Giros B, Schwartz JC. (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol, 225 (4): 331-7. [PMID:1354163]

133. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347 (6289): 146-51. [PMID:1975644]

134. Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. (2013) Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol, 386 (2): 107-24. [PMID:23001156]

135. Song R, Zhang HY, Li X, Bi GH, Gardner EL, Xi ZX. (2012) Increased vulnerability to cocaine in mice lacking dopamine D3 receptors. Proc Natl Acad Sci USA, 109 (43): 17675-80. [PMID:23045656]

136. Spetea M, Berzetei-Gurske IP, Guerrieri E, Schmidhammer H. (2012) Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist. J Med Chem, 55 (22): 10302-6. [PMID:23134120]

137. Starr MS, Starr BS. (1995) Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors. Eur J Pharmacol, 277 (2-3): 151-8. [PMID:7493603]

138. Steiner H, Fuchs S, Accili D. (1997) D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav, 63 (1): 137-41. [PMID:9402626]

139. Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N. (1994) Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol, 263 (3): 235-43. [PMID:7843260]

140. Svensson K, Carlsson A, Waters N. (1994) Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect, 95 (1): 71-4. [PMID:7857588]

141. Tang L, Todd RD, Heller A, O'Malley KL. (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther, 268 (1): 495-502. [PMID:8301592]

142. Tang L, Todd RD, O'Malley KL. (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther, 270 (2): 475-9. [PMID:8071839]

143. Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD. (1994) Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem Behav, 49 (3): 567-71. [PMID:7862709]

144. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350 (6319): 610-4. [PMID:1840645]

145. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H. (2009) Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett, 19 (2): 538-42. [PMID:19091563]

146. Waters N, Löfberg L, Haadsma-Svensson S, Svensson K, Sonesson C, Carlsson A. (1994) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect, 98 (1): 39-55. [PMID:7710738]

147. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect, 94 (1): 11-9. [PMID:8129881]

148. Werner P, Hussy N, Buell G, Jones KA, North RA. (1996) D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol Pharmacol, 49 (4): 656-61. [PMID:8609893]

149. Xi ZX, Gardner EL. (2007) Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev, 13 (2): 240-59. [PMID:17627675]

150. Xi ZX, Gilbert J, Campos AC, Kline N, Ashby Jr CR, Hagan JJ, Heidbreder CA, Gardner EL. (2004) Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl.), 176 (1): 57-65. [PMID:15083257]

151. Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE et al.. (2014) Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. J Med Chem, 57 (8): 3450-63. [PMID:24666157]

152. Xu M, Caine SB, Cooper DC, Gold LH, Graybiel AM, Hu XT, Loeltzow T, Koob GF, Moratalla R, White FJ, Tonegawa S. (1995) Analysis of dopamine D3 and D1 receptor mutant mice. (Abstract) Soc Neurosci Abst, 21: 363-.

153. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S. (1997) Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron, 19 (4): 837-48. [PMID:9354330]

154. Yamada S, Yokoo H, Nishi S. (1994) Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res, 648 (1): 176-9. [PMID:7922522]

155. Yu C, Yang Z, Ren H, Zhang Y, Han Y, He D, Lu Q, Wang X, Wang X, Yang C et al.. (2009) D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. Am J Hypertens, 22 (8): 877-83. [PMID:19390510]

156. Zhang Y, Fu C, Asico LD, Villar VA, Ren H, He D, Wang Z, Yang J, Jose PA, Zeng C. (2011) Role of Gα(12)- and Gα(13)-protein subunit linkage of D(3) dopamine receptors in the natriuretic effect of D(3) dopamine receptor in kidney. Hypertens Res, 34 (9): 1011-6. [PMID:21633357]

157. Zhen J, Antonio T, Dutta AK, Reith ME. (2010) Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. J Neurosci Methods, 188 (1): 32-8. [PMID:20122961]

Contributors

Show »

How to cite this page